Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma (NCT05398133) | Clinical Trial Compass
UnknownNot Applicable
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Poland36 participantsStarted 2020-09-01
Plain-language summary
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma. The aim of this study was to assess the expression of selected surface markers on eosinophils and to assess the gene expression in eosinophils in COPD and asthma patients. We are planning to enrol 12 COPD, 12 asthma and 12 control subjects. Patients will undergo routine clinical assessment, spirometry, blood sampling and sputum induction. Eosinophils will be isolated from blood and sputum. Surface markers on eosinophils will be assessed in flow cytometry, gene expression will be assessed by RNAseq.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of COPD according to GOLD 2019 or asthma according to GINA 2021
* Peripheral blood eosinophil count ≥ 100 / μL
* Age ≥40 years (COPD), ≥18 years (asthma)
* History of cigarette smoking: ≥10 pack-years (for COPD)
* Stable disease period (at least 3 months without exacerbation)
* Exclusion of parasitic diseases
* Informed consent to participate in the study
Exclusion Criteria:
* COPD and asthma overlap
* Use of systemic corticosteroids in the 3 months prior to the study
* Respiratory infection or exacerbation in the 3 months prior to the study
* Acute and chronic respiratory failure
* Concomitant diagnoses: systemic connective tissue diseases, malignant neoplasms, severe and / or uncontrolled cardiovascular diseases
* Use of immunosuppressive or immunomodulating drugs in the 3 months preceding the study
* Contraindications to sputum induction
* No consent to participate in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
expression of surface markers
Timeframe: performed up to 3 months after blood and sputum collection